FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Q / Dynamics of acylcarnitines, hypoglycin A, méthylènecyclopr...
The veterinary quarterly2022; 42(1); 183-191; doi: 10.1080/01652176.2022.2126537

Dynamics of acylcarnitines, hypoglycin A, méthylènecyclopropylglycine and their metabolites in a Kladruber stallion with atypical myopathy.

Abstract: Equine atypical myopathy (AM also referred to as multiple acyl-CoA dehydrogenases deficiency [MADD]) is thought to be caused by toxins metabolized from hypoglycin A (HGA) and méthylènecyclopropylglycine (MCPrG). HGA is contained in the seeds and seedlings of the sycamore tree (Acer pseudoplatanus); MCPrG has so far only been confirmed in seeds. Among other things, these substances can disrupt the fatty acids β-oxidation pathway with the subsequent accumulation of certain acylcarnitines. The tentative diagnosis is based on anamnesis and clinical signs and can be verified by the detection of elevated creatine kinase activity, specific profile of acylcarnitines and the presence of HGA, MCPrG conjugates and/or their metabolites in peripheral blood and/or urine. Dry blood spots were collected for 15 days from a 3.5-year-old stallion which had been affected by AM and, as a control group, from twelve healthy horses. Two mass spectrometry methods were used for the analysis of 31 acylcarnitines, carnitine, HGA, MCPrG and their metabolites. HGA and six increased acylcarnitines were detected in the patient's blood throughout the monitoring period. Nine acylcarnitines were strongly correlated with HGA. Multivariate statistical analysis showed a clear separation of samples from the AM horse, where the metabolic profile tended to normalization in the later days after intoxication. Due to the longer persistence in the blood, the detection of HGA and elevated acylcarnitines profile appear to be an appropriate tool to confirm the diagnosis of AM, compared to metabolic products of HGA and MCPrG even in advanced cases.
Get Full Text
Publication Date: 2022-09-18 PubMed ID: 36114619PubMed Central: PMC9518284DOI: 10.1080/01652176.2022.2126537Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the features of Atypical Myopathy (AM) in a Kladruber stallion thought to be caused by the toxins produced from hypoglycin A (HGA) and méthylènecyclopropylglycine (MCPrG). Biomarkers within blood and urine such as acylcarnitines, HGA, MCPrG, and their metabolic products were observed. The results show that these biomarkers can be used for detection and confirmation of AM.

Overview of the Research

  • The focus of the research is on equine atypical myopathy (AM), a disorder believed to be caused by toxins metabolized from two specific substances, hypoglycin A (HGA) and méthylènecyclopropylglycine (MCPrG).
  • These toxins are known to disrupt the fatty acids β-oxidation pathway, leading to accumulation of certain acylcarnitines. This disruption and irregularity serve as potential indicators of the disorder.
  • The examination was carried out on blood samples from a 3.5-year-old stallion diagnosed with AM, over a period of 15 days. In addition, twelve samples from healthy horses were used as control.

Methodology

  • Two mass spectrometry methods were employed to analyze a total of 31 acylcarnitines, carnitine, HGA, MCPrG, and their corresponding metabolic byproducts.
  • The presence of HGA and six increased acylcarnitines were monitored and verified in the patient’s blood for the duration of the testing period.
  • Statistical analysis revealed a strong correlation between nine acylcarnitines and HGA. These samples were distinct compared to those from the healthy horses, indicating clear differences in metabolic profiles.

Findings and Conclusion

  • The researchers found that the metabolic profile of the AM-affected horse trended towards normalization in the later days post-intoxication, separating its sample from the unaffected horses.
  • The lasting presence of HGA and elevated acylcarnitines in the blood suggests that these discriminant features could be used to confirm the diagnosis of AM.
  • The research suggests that this approach could be useful even in more progressed cases, offering a more reliable diagnostic tool compared to traditional methods that rely mainly on metabolic products of HGA and MCPrG.

Cite This Article

APA
Jahn P, Dobešová D, Brumarová R, Tóthová K, Kopecká A, Friedecký D. (2022). Dynamics of acylcarnitines, hypoglycin A, méthylènecyclopropylglycine and their metabolites in a Kladruber stallion with atypical myopathy. Vet Q, 42(1), 183-191. https://doi.org/10.1080/01652176.2022.2126537

Publication

The veterinary quarterly
ISSN: 1875-5941
NlmUniqueID: 7909485
Country: England
Language: English
Volume: 42
Issue: 1
Pages: 183-191

Researcher Affiliations

Jahn, Petr
  • Equine Clinic, Faculty of Veterinary Medicine, University of Veterinary Sciences, Brno, Czech Republic.
Dobešová, Dana
  • Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
Brumarová, Radana
  • Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
Tóthová, Katarína
  • Equine Clinic, Faculty of Veterinary Medicine, University of Veterinary Sciences, Brno, Czech Republic.
Kopecká, Andrea
  • Equine Clinic, Faculty of Veterinary Medicine, University of Veterinary Sciences, Brno, Czech Republic.
Friedecký, David
  • Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.

MeSH Terms

  • Acyl-CoA Dehydrogenases
  • Animals
  • Carnitine / analogs & derivatives
  • Creatine Kinase
  • Cyclopropanes
  • Fatty Acids
  • Glycine / analogs & derivatives
  • Horse Diseases / diagnosis
  • Horses
  • Hypoglycins
  • Male
  • Muscular Diseases / diagnosis
  • Muscular Diseases / veterinary

Conflict of Interest Statement

No potential conflict of interest was reported by the authors.

References

This article includes 29 references
  1. AlzbetaG. AlzbetaG/Metabol: First version 2019 May 30. [accessed 2022 Jul 1]. https://zenodo.org/record/3235775.
  2. Bochnia M, Sander J, Ziegler J, Terhardt M, Sander S, Janzen N, Cavalleri J-MV, Zuraw A, Wensch-Dorendorf M, Zeyner A. Detection of MCPG metabolites in horses with atypical myopathy. PLoS One 2019;14(2):e0211698.
    pmc: PMC6363182pubmed: 30721263
  3. Bochnia M, Scheidemann W, Ziegler J, Sander J, Vollstedt S, Glatter M, Janzen N, Terhardt M, Zeyner A. Predictive value of hypoglycin A and methylencyclopropylacetic acid conjugates in a horse with atypical myopathy in comparison to its cograzing partners. Equine Vet Educ 2018;30(1):24–28.
  4. Bochnia M, Ziegler J, Sander J, Uhlig A, Schaefer S, Vollstedt S, Glatter M, Abel S, Recknagel S, Schusser GF. Hypoglycin A content in blood and urine discriminates horses with atypical myopathy from clinically normal horses grazing on the same pasture. PLoS ONE 2015;10(9):e0136785.
    pmc: PMC4574941pubmed: 26378918
  5. Boemer F, Detilleux J, Cello C, Amory H, Marcillaud-Pitel C, Richard E, van Galen G, van Loon G, Lefère L, Votion D-M. Acylcarnitines profile best predicts survival in horses with atypical myopathy. PLoS One 2017;12(8):e0182761.
    pmc: PMC5573150pubmed: 28846683
  6. Carlier J, Guitton J, Moreau C, Boyer B, Bévalot F, Fanton L, Habyarimana J, Gault G, Gaillard Y. A validated method for quantifying hypoglycin A in whole blood by UHPLC-HRMS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2015;978–979:70–77.
    pubmed: 25531872
  7. Dunkel B, Ryan A, Haggett E, Knowles EJ. Atypical myopathy in the South‐East of England: clinicopathological data and outcome in hospitalised horses. Equine Vet Educ 2020;32(2):90–95.
  8. Fabius LS, Westermann CM. Evidence-based therapy for atypical myopathy in horses. Equine Vet Educ 2018;30(11):616–622.
  9. Finno CJ, Valberg SJ, Wünschmann A, Murphy MJ. Seasonal pasture myopathy in horses in the midwestern United States: 14 cases (1998–2005). J Am Vet Med Assoc 2006;229(7):1134–1141.
    pubmed: 17014363
  10. González-Medina S, Ireland JL, Piercy RJ, Newton JR, Votion DM. Equine atypical myopathy in the UK: Epidemiological characteristics of cases reported from 2011 to 2015 and factors associated with survival. Equine Vet J 2017;49(6):746–752.
    pubmed: 28445006
  11. Gröndahl G, Berglund A, Skidell J, Bondesson U, Salomonsson M. Clinical research abstracts of the British Equine Veterinary Association Congress 2015. Equine Vet J 2015;47(Suppl 48):22.
    pubmed: 26375998
  12. Karlíková R, Široká J, Jahn P, Friedecký D, Gardlo A, Janečková H, Hrdinová F, Drábková Z, Adam T. Equine atypical myopathy: a metabolic study. Vet J 2016;216:125–132.
    pubmed: 27687939
  13. Karlíková R, Široká J, Mech M, Friedecký D, Janečková H, Mádrová L, Hrdinová F, Drábková Z, Dobešová O, Adam T. Newborn foal with atypical myopathy. J Vet Intern Med 2018;32(5):1768–1772.
    pmc: PMC6189353pubmed: 30216546
  14. Luís PBM, Ruiter JPN, Ijlst L, Tavares de Almeida I, Duran M, Mohsen A-W, Vockley J, Wanders RJA, Silva MFB. Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: implications for the branched-chain amino acid oxidation pathway. Drug Metab Dispos 2011;39(7):1155–1160.
    pmc: PMC3127238pubmed: 21430231
  15. Mathis D, Sass JO, Graubner C, Schoster A. Diagnosis of atypical myopathy based on organic acid and acylcarnitine profiles and evolution of biomarkers in surviving horses. Mol Genet Metab Rep 2021;29:100827.
    pmc: PMC8639802pubmed: 34900597
  16. Sander J, Cavalleri J-MV, Terhardt M, Bochnia M, Zeyner A, Zuraw A, Sander S, Peter M, Janzen N. Rapid diagnosis of hypoglycin A intoxication in atypical myopathy of horses. J Vet Diagn Invest 2016;28(2):98–104.
    pubmed: 26965229
  17. Sander J, Terhardt M, Janzen N. Study on the metabolic effects of repeated consumption of canned ackee. J Agric Food Chem 2020;68(49):14603–14609.
    pubmed: 33233889
  18. Sander J, Terhardt M, Sander S, Janzen N. Use of a standard newborn screening test for the rapid diagnosis of inhibited ß-oxidation in atypical myopathy in horses. J Equine Vet Sci 2018;67:71–74.
  19. Sponseller BT, Valberg SJ, Schultz NE, Bedford H, Wong DM, Kersh K, Shelton GD. Equine multiple acyl-CoA dehydrogenase deficiency (MADD) associated with seasonal pasture myopathy in the midwestern United States. J Vet Intern Med 2012;26(4):1012–1018.
    pubmed: 22708588
  20. Toutain PL, Lassourd V, Costes G, Alvinerie M, Bret L, Lefebvre HP, Braun JP. A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. J Vet Pharmacol Ther 1995;18(3):226–235.
    pubmed: 7674460
  21. Valberg SJ, Sponseller BT, Hegeman AD, Earing J, Bender JB, Martinson KL, Patterson SE, Sweetman L. Seasonal pasture myopathy/atypical myopathy in North America associated with ingestion of hypoglycin A within seeds of the box elder tree. Equine Vet J 2013;45(4):419–426.
    pubmed: 23167695
  22. Van Galen G, Amory H, Busschers E, Cassart D, De Bruijn M, Gerber V, Keen J, Lefere L, Pitel CM, Marr C. European outbreak of atypical myopathy in the autumn 2009. J Vet Emerg Crit Care (San Antonio) 2010;20(5):528–532.
    pubmed: 20955305
  23. van Galen G, Marcillaud Pitel C, Saegerman C, Patarin F, Amory H, Baily JD, Cassart D, Gerber V, Hahn C, Harris P. European outbreaks of atypical myopathy in grazing equids (2006–2009): spatiotemporal distribution, history and clinical features. Equine Vet J 2012;44(5):614–620.
    pubmed: 22448904
  24. van Galen G, Saegerman C, Marcillaud Pitel C, Patarin F, Amory H, Baily JD, Cassart D, Gerber V, Hahn C, Harris P. European outbreaks of atypical myopathy in grazing horses (2006–2009): determination of indicators for risk and prognostic factors. Equine Vet J 2012;44(5):621–625.
    pubmed: 22413891
  25. Votion D-M, Linden A, Saegerman C, Engels P, Erpicum M, Thiry E, Delguste C, Rouxhet S, Demoulin V, Navet R. History and clinical features of atypical myopathy in horses in Belgium (2000–2005). J Vet Intern Med 2007;21(6):1380–1391.
    pubmed: 18196750
  26. Votion DM, Serteyn D. Equine atypical myopathy: a review. Vet J 2008;178(2):185–190.
    pubmed: 18375157
  27. Votion D-M, van Galen G, Sweetman L, Boemer F, de Tullio P, Dopagne C, Lefère L, Mouithys-Mickalad A, Patarin F, Rouxhet S. Identification of methylenecyclopropyl acetic acid in serum of European horses with atypical myopathy. Equine Vet J 2014;46(2):146–149.
    pubmed: 23773055
  28. Westermann CM, Dorland L, Votion DM, de Sain-van der Velden MGM, Wijnberg ID, Wanders RJA, Spliet WGM, Testerink N, Berger R, Ruiter JPN. Acquired multiple Acyl-CoA dehydrogenase deficiency in 10 horses with atypical myopathy. Neuromuscul Disord 2008;18(5):355–364.
    pubmed: 18406615
  29. Witkowska-Pilaszewicz O, Kaszak I, Zmigrodska M, Winnicka A, Sacharczuk M, Szczepaniak J, Cywinska A. Equine Atypical myopathy – a review. Anim Sci Pap Rep 2019;37(3):233–242.
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.